Daniel Long Sells 15,000 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 15,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,423,590.12. This trade represents a 13.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Septerna Stock Down 4.2%

NASDAQ:SEPN opened at $34.54 on Friday. Septerna, Inc. has a twelve month low of $10.26 and a twelve month high of $37.99. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -42.64 and a beta of 2.39. The stock’s 50 day moving average price is $29.01 and its two-hundred day moving average price is $27.29.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The company had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. As a group, analysts anticipate that Septerna, Inc. will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Group One Trading LLC lifted its holdings in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after buying an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new position in shares of Septerna in the fourth quarter valued at about $35,000. Russell Investments Group Ltd. bought a new position in Septerna during the third quarter worth about $36,000. Caitong International Asset Management Co. Ltd bought a new position in Septerna during the fourth quarter worth about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna in the 4th quarter worth about $61,000.

Wall Street Analysts Forecast Growth

SEPN has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 price objective on shares of Septerna in a research note on Tuesday, March 10th. Truist Financial raised their target price on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. JPMorgan Chase & Co. lifted their price target on Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Wells Fargo & Company boosted their price target on Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Septerna in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.78.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.